Your search for ESKD returned 10 results

Patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis express a desire to exercise to regain energy and strength, but many report barriers to exercise.

For patients with type 2 diabetes, intensive glucose control has long-term benefits for preventing end-stage kidney disease (ESKD), according to a study published online March 22 in Diabetes Care.

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.

“We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes,” write the authors.

Based on these studies, it would appear that dietary changes could prevent 1 in every 3,000 people treated for 1 year avoid ESKD, however the certainty in this effect was very low.

A recent study examines the benefits and harms of vitamin B therapy in patients with diabetic kidney disease.

Can gabapentin relieve two common symptoms associated with chronic kidney disease (CKD) and end-stage kidney disease (ESKD)?